XYL Stock Price Today (September 2026) — Xylem Inc. Analysis & Key Metrics 2026-09-03
Xylem Inc. (XYL) is trading at $107.89, up 1.08% today (as of September 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Industrials growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $153.88 (42.6% upside).
- Volatility remains elevated (20.72% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (1.50% YoY) alongside significant competitive pressures.
XYL Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Xylem Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $27.73B
P/E Ratio
Forward P/E: 17.63
Revenue Growth
Year over Year
Analyst Target
+42.6% upside potential
Key Investor Questions About XYL
What investors need to know before buying
Based on current market data, XYL presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 30.15)
- Fundamentals say: Caution warranted (high leverage concerns)
XYL's growth trajectory depends on its ability to expand within the Specialty Industrial Machinery sector while managing margin pressures.
- Future growth will depend on performance in core Specialty Industrial Machinery operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for XYL investors include debt exposure and competitive dynamics in the Specialty Industrial Machinery industry.
- $3.06B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Specialty Industrial Machinery.
52-Week Trading Range
Over the past year, XYL stock traded between $105.29 and $154.27—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.72% annualized volatility and β=0.87, the stock exhibits moderate correlation to market moves—making XYL suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Xylem (XYL) Down 7.1% Since Last Earnings Report: Can It Rebound?
Xylem (XYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GE HealthCare Technologies (GEHC) Names A New CFO As Its Undervalued Narrative Faces A Test
GE HealthCare Technologies (GEHC) has drawn fresh attention after announcing William K. Grogan as its incoming Chief Financial Officer, effective September 14, 2026, following his finance leadership roles at Xylem and IDEX. For investors watching GE HealthCare Technologies, the recent CFO news comes after a strong 30 day share price return of 22% and a 90 day share price return of 15.7%. However, the year to date share price return is down 10.76%, and the 1 year total shareholder return is...
Xylem (XYL) Could Be 23% Below Fair Value Following Its Q2 Profit Outlook Lift
Xylem (XYL) is back in focus after its Q2 FY2026 results showed stronger profitability. The company raised adjusted EPS guidance and improved its adjusted EBITDA margin outlook, despite trimming its full year revenue forecast. See our latest analysis for Xylem. Xylem's latest earnings update has arrived after a mixed share price run, with the stock at US$116.21 and a year to date share price return down 15.24%, while the 3 year total shareholder return of 19.86% contrasts with a 1 year total...
What Should Xylem (XYL) Investors Make Of Its New CFO And Board Pick?
Xylem (NYSE:XYL) appointed Andrea van der Berg as Chief Financial Officer and Executive Vice President. The company also added D. Christian Koch to its Board of Directors. These leadership changes highlight a refreshed focus on financial oversight and board-level experience. Leadership moves at Xylem keep attention on companies that prioritize resilient balance sheets and steadier earnings profiles, which makes it worth looking at a broader group of lower-risk stocks through 79 resilient...
GE HealthCare names new CFO
William Grogan will take over the chief finance job vacated by Jay Saccaro. Stifel analysts called Grogan’s “no-nonsense” mindset on setting expectations a strength.
Xylem Stock: Analyst Estimates & Ratings
Xylem has underperformed the broader market, while analysts remain moderately optimistic about its future prospects.
Is WTS Worth Buying as Fast Growth Collides With Premium Valuation?
WTS pairs faster earnings growth and booming data center sales with a premium valuation, leaving little room for execution misses.
Is VLTO Worth Buying as Growth Improves but Valuation Stays Rich?
Veralto's earnings momentum, recurring revenues and liquidity strengthen its growth case, but a premium valuation favors a selective approach.
VLTO Climbs 13.2% in 3 Months: Will Its Momentum Keep Building Now?
Veralto's Water Quality growth, margin gains and raised 2026 guidance support momentum, but its premium valuation raises the bar for execution.
Badger Meter's Growth Story Hinges on Cellular AMI and BlueEdge Demand
Badger Meter's growth hinges on cellular AMI, recurring software and BlueEdge demand, while uneven project timing and cost pressures cloud 2026.
Explore More Analysis for XYL
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Xylem Inc.
Xylem Inc. (XYL) is currently trading at $107.89. The RSI (14-day) is at 30.1, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $153.88 implies 42.6% upside from current levels. Volatility is moderate at 20.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Xylem Inc. (XYL): The trailing P/E ratio is 26.00, which is in line with broader market averages. The forward P/E is 17.63, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.53, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 2.29. Price-to-Sales is 2.76. Valuation should be compared to Specialty Industrial Machinery industry peers for context, as different sectors trade at different multiples.
Based on 16 analysts covering XYL, the consensus price target is $153.88. This represents a 42.6% upside from the current price of $107.89. The range spans from a low target of $129.00 to a high target of $180.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Xylem Inc. (XYL) pays a dividend with a current yield of approximately 1.59%. The annualized dividend rate is $1.66 per share. The payout ratio is 39.5%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-08-27T00:00:00.000Z.
Key risks for Xylem Inc. (XYL) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Specialty Industrial Machinery sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Xylem Inc.'s (XYL) current debt and financial health profile: Total debt stands at $3.06B. The debt-to-equity ratio is 28.64, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 1.61, indicating strong short-term liquidity. The quick ratio is 1.16. The company holds $1.28B in cash and equivalents. Free cash flow is positive at $1.18B, providing a cushion for debt servicing and shareholder returns.